Other formats:
BibTeX
LaTeX
RIS
@article{1461578, author = {Češková, Eva and Šedová, M. and Kellnerova, R. and Starobová, Olga}, article_location = {BASEL}, article_number = {3-4}, doi = {http://dx.doi.org/10.1159/000492079}, keywords = {Trazodone; Depression; Clinical practice; Treatment-resistant depression; Individualized treatment; Multimodal antidepressant}, language = {eng}, issn = {0031-7012}, journal = {PHARMACOLOGY}, title = {Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice}, url = {https://www.karger.com/Article/FullText/492079}, volume = {102}, year = {2018} }
TY - JOUR ID - 1461578 AU - Češková, Eva - Šedová, M. - Kellnerova, R. - Starobová, Olga PY - 2018 TI - Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice JF - PHARMACOLOGY VL - 102 IS - 3-4 SP - 206-212 EP - 206-212 PB - KARGER SN - 00317012 KW - Trazodone KW - Depression KW - Clinical practice KW - Treatment-resistant depression KW - Individualized treatment KW - Multimodal antidepressant UR - https://www.karger.com/Article/FullText/492079 N2 - Objective: The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a day trazodone tablets (Trittico Prolong (R) 300 mg) in patients with moderate to severe depression in routine clinical practice. Methods: Men and women >= 18 years old with Montgomery-Asberg Depression Rating Scale (MADRS) scores >21 and Clinical Global Impression - Severity (CGI/S) >= 4 were included in this post-authorization, non-interventional, observational prospective safety study, conducted in 8 psychiatric centers in the Czech Republic. The acute treatment phase lasted 5 weeks: 1 week of titration and 4 weeks of full-dose treatment. Patients had follow-up visits 9 and 21 weeks after commencing treatment. Results: Overall, 85 patients were enrolled in the study, of which 80 completed the acute treatment of 5 weeks. There were significant decreases in the overall MADRS score from the baseline mean value of 27.4-21.2 at week 1 (p < 0.001), and a further decrease to 7.9 at week 5 (p < 0.001). The severity of depression according to CGI/S gradually declined. Most patients reported improvement after 6 days of trazodone treatment. The most frequent adverse drug reactions (ADRs) reported were somnolence and fatigue. Conclusions: Trazodone, in the new extended-release formulation, had very good effects in clinical practice, both in previously untreated depressive episodes and in episodes not responsive to previous antidepressive therapy. (C) 2018 S. Karger AG, Basel ER -
ČEŠKOVÁ, Eva, M. ŠEDOVÁ, R. KELLNEROVA and Olga STAROBOVÁ. Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice. \textit{PHARMACOLOGY}. BASEL: KARGER, 2018, vol.~102, 3-4, p.~206-212. ISSN~0031-7012. Available from: https://dx.doi.org/10.1159/000492079.
|